

Synthesis and characterization of steroidal, anellated aminothiophenes by Gewald reaction

Oliver Kraft¹, Gregor C. Mittag¹, Sophie Hoenke¹, Niels Heise¹, Ahmed Al-Harrasi² and René Csuk^{1,*}

¹ Martin-Luther-University Halle-Wittenberg, Organic Chemistry, Kurt-Mothes-Str. 2, D-06120 Halle (Saale), Germany

² University of Nizwa, Chair of Oman's Medicinal Plants and Marine Natural Products, P.O. Box 33, PC 616, Birkat Al-Mauz, Nizwa, Sultanate of Oman

Abstract: Gewald 3-component reactions (G-3CR), i.e., reactions of a carbonyl compound with an activated nitrile in the presence of a secondary amine and sulfur, lead straightforwardly to anellated 2-aminothiophenes. Interestingly, their application to steroidal hydrocarbons has been limited to a single example. We were able to show in this work that Gewald 3-component reactions can be performed successfully for molecules holding a cholesterol or sitostanol skeleton, such as 5 α -cholestan-3-one (**8**) and 5 α -sitostan-3-one (**11**), thus leading in good yields to the corresponding anellated steroidal 2-amino-thiophenes **12-15**. Gewald reaction proved to be an excellent method to access heterocyclic steroids.

Keywords: Aminothiophenes; Gewald reaction; steroids.


1. Introduction

Heterocyclic steroids demonstrated potent bioactivity due to the incorporation of a fused heterocyclic ring into the steroid skeleton¹. Many routes have been devised for their synthesis¹⁻⁴. Thereby, the synthesis of 2-aminothiophenes⁵⁻¹¹ has been the focus of organic chemists for many years. They found applications as pharmaceuticals^{6,12-17} but also in agriculture and for dyeing processes¹⁸. Albeit many different synthetic schemes have been described for their synthesis; it was the merit of K. Gewald¹⁹⁻²⁴ as early as 1966 to describe a multi-component reaction²⁵⁻³² (MCR, G-3CR as an abbreviation for Gewald-3-component reaction)^{13,15,18,33-36}. Thereby a carbonyl compound **A** (Scheme 1) is allowed to react with an activated nitrile **B** and sulfur in the presence of a secondary amine to yield a poly-substituted

2-aminothiophene **C**. MCRs allow the convergent synthesis of a wide variety of compounds thus improving the efficacy to explore chemical space in a fast, cost-effective and convergent manner with a minimum of synthetic effort. Although many Gewald reactions have been described, a close inspection of the literature revealed only one example of a Gewald reaction using a steroidal hydrocarbon. A different scheme has been prepared³⁷. Two molecules of a similar structure have shown some anti-bacterial and antifungal activity³⁸. This is all the more surprising as the interest in sterols, especially phytosterols, has increased. This class of compounds might be used to lower blood cholesterol levels, reducing the risk of cardiovascular disease³⁹⁻⁴². Some phytosterols have been reported to have prophylactic anticancer and cytotoxic activity⁴³ on lung, stomach, ovarian, and breast cancer cell lines⁴⁴⁻⁴⁸.

*Corresponding author: René Csuk
Email address: rene.csuk@chemie.uni-halle.de
DOI: <http://dx.doi.org/10.13171/mjc02209261446csuk>

Received August 10, 2022
Accepted September 2, 2022
Published September 26, 2022




Scheme 1. Mechanism of the Gewald-3-component (G-3CR) reaction. The reaction of a carbonyl compound (A) with a cyano ester (B) in the presence of a secondary amine and sulfur leads to a 2-aminothiophene (C)

2. Results and Discussion

Mechanistically, as depicted in [Scheme 1](#), the first step of a G-3CR reaction is a Knoevenagel condensation between the carbonyl compound and the α -cyanoester to yield an α -alkylidene nitrile, which cyclizes in a subsequent step when reacted with elemental sulfur to afford the target product, 2-aminothiophene ^{49,50}. Since no reaction occurred in a reaction of 3-oxo-cholesterol with ethyl α -cyanoacetate in the presence of morpholine and sulfur at room temperature, deterioration and rearrangement reactions became dominant under reflux or in a microwave-assisted synthesis. The reaction was studied in more detail on a few model compounds.


The rearrangement reactions observed in the conversion of 3-oxo-cholesterol paralleling previous results during Willgerodt-Kindler reactions ⁵¹. Thus, for optimization, cyclohexanone (**1**), methylcyclohexanones (**2** and **3**) were each reacted with ethyl α -cyanoacetate in the presence of morpholine and sulfur ([Scheme 2](#)). While cyclohexanone (**1**) and 2-methyl-cyclohexanone (**2**) gave products **4** and **5** in excellent yield in the Gewald reaction, 3-methyl-cyclohexanone (**3**) gave only the 5-methyl isomer **6**. This finding reflects an apparent stereo-electronic influence of substituents on the reaction and its course. This is probably also why, for example, the pentacyclic triterpenes 3-oxo-oleanolic acid and 3-oxo-platanic acid gave no isolable reaction products in Gewald reactions.



Scheme 2. Gewald reaction of cyclohexanone and methyl-cyclohexanones following General Procedure GP1: **1**-**3**, ethyl cyanoacetate, S_8 , morpholine, 21°C, 1d; yields: **4** (54.5% from **1**), **5** (83.2% from **2**), **6** (84.6% from **3**)

Jones oxidation ([Scheme 3](#)) of (+)-dihydrocholesterol (**7**) gave 87% of **5**. Sitostanol (**9**; obtained in 83% yield by hydrogenolysis from stigmasterol (**10**) with Pd/C and H_2 , 48 h, 5 bar) was also converted to ketone **11** by Jones oxidation. The stereochemical course of hydrogenolysis of **10** is directed by the position of the methyl group C-19 ⁵². The physicochemical data obtained for **8** and **11** are in excellent agreement with

those reported in the literature. Thus, the vibrations of the carbonyl group for **5** and **7** were detected at $\nu = 1713$ and 1716 cm^{-1} , respectively. In the ^{13}C NMR spectrum, each case finds the corresponding signal at $\delta = 212.0$ ppm. The reaction of **8** and **11** with ethyl α -cyanoacetate or propyl α -cyanoacetate gave the annellated 2-aminothiophenes **12–15** in 58-67% isolated yield.



Scheme 3. Synthesis of steroidal scaffolds **8** and **11** and their Gewald reactions leading to products **12–15**. Reactions and conditions: a) Jones oxidation (CrO₃, H₂O, H₂SO₄, silica gel, 0°C, 2h); yields: 87.5% of **8**, 59.7% of **11**; b) H₂ (5 bar), Pd/C, THF/MeOH, 2:1, 48h, 83.4%; c) following GP1 (ethyl cyanoacetate or propyl cyanoacetate, S₈, morpholine, 21 °C, 1d: yields: **12** (57.6%), **13** (66.9%), **14** (61.8%), **15** (64.3%)

These compounds are characterized by a UV/Vis maximum $\lambda_{\text{max}} = 230$ nm; the carbonyl group of the ester shows up in the IR spectra at $\nu = 1663\text{--}1665$ cm⁻¹; the carboxyl group is found in the ¹³C NMR spectrum at $\delta = 165.9\text{--}166.1$ ppm. The quasi-molecule ions $m/z = 514$ (for **12**), 528 (for **13**), 542 (for **14**) and 556 (for **15**) further confirm the structure of the Gewald products.

The study of phytochemical activity is currently the subject of further investigation; of particular interest will be the activity of these compounds and analogs thereof onto the enzyme anandamide amidohydrolase to treat anxiety disorders⁵³⁻⁵⁷ onto the orexin

receptor⁵⁸⁻⁶⁴ to treat narcolepsy or insomnia. A mandatory prerequisite for these applications is that the compounds are not (cyto)-toxic. Sulforhodamine B assays employing several human cancer cell lines [A375 (melanoma), HT29 (colorectal carcinoma), MCF-7 (breast adenocarcinoma), A2780 (ovarian carcinoma), FaDu (pharynx carcinoma)] as well as fibroblasts (NIH 3T3) resulted in EC₅₀ values > 30 μM ; thus, these compounds are to be considered as non-cytotoxic. Furthermore, potential neurotoxicity can also be excluded with high probability since compounds **12-15** showed no inhibitory effect on the enzymes acetylcholinesterase (eeAChE) and butyrylcholinesterase (BChE).

3. Conclusion

The Gewald reaction had hardly been applied to steroidal systems before. We were now able to. Moreover, we could show in this work that Gewald 3-component reactions can also be carried out successfully for this class of compounds, thus leading in good yields to the corresponding anellated 2-amino-thiophenes.

4. Experimental

NMR spectra were recorded using the Varian spectrometers (Darmstadt, Germany) DD2 and VNMRs (400 and 500 MHz, respectively). MS spectra were taken on an Advion expression LCMS mass spectrometer (Ithaca, NY, USA; positive ion polarity mode, solvent: methanol, solvent flow: 0.2 mL/min, spray voltage: 5.17 kV, source voltage: 77 V, APCI corona discharge: 4.2 μ A, capillary temperature: 250°C, capillary voltage: 180 V, sheath gas: N₂). Thin-layer chromatography was performed on pre-coated silica gel plates supplied by Macherey-Nagel (Düren, Germany). IR spectra were recorded on a Spectrum 1000 FT-IR-spectrometer from Perkin Elmer (Rodgau, Germany). The UV/Vis-spectra were recorded on a Lambda 14 spectrometer from Perkin Elmer (Rodgau, Germany); optical rotations were measured at 20°C using a JASCO-P2000 instrument (JASCO Germany GmbH, Pfungstadt, Germany). The melting points were determined using a Leica hot stage microscope Galen III (Leica Biosystems, Nussloch, Germany) and are uncorrected. The solvents were dried according to usual procedures. Microanalyses were performed with an Elementar Vario EL (CHNS) instrument (Elementar Analysensysteme GmbH, Elementar-Straße 1, D-63505, Langenselbold, Germany).

General procedure for the Gewald reaction (GP1)

To a suspension of the starting material (**1-3**, **8**, **11**, 1 eq.) in dry EtOH (15 mL), the cyanoester (1 eq.), and sulfur (1 eq.) were added; freshly distilled morpholine (1 eq) was added dropwise, and the mixture was stirred at room temperature for 1 day. Then, the volatiles were removed under reduced pressure, and the residue was purified either by re-crystallization or column chromatography to yield products **4-6** and **12-15**, respectively.

General procedure for the Jones oxidation (GP2)

To a suspension of the sterol (**7** or **9**, 1 eq.) in acetone (125 mL), silica gel (20 mL) was added, and the mixture was heated under reflux for 20 min and after cooling to 0°C, freshly prepared Jones reagent [from CrO₃ (0.78 g, 7.76 mmol), dist. H₂O (2.5 mL), conc. H₂SO₄ (0.75 mL)] was added, and the reaction was stirred for 2 h at 0°C. For work-up, MeOH (1 mL) was added, and stirring at room temperature continued for another 90 min. Finally, the volatiles were removed under reduced pressure, the residue extracted (Et₂O, Soxhlet apparatus, 5 h), the solvent was removed, and

the residue subjected to chromatography to yield **8** and **11**, respectively.

2-Amino-4,5,6,7-tetrahydro-benzo[b]-thiophene-3-carboxylic acid ethyl ester (**4**)

Following GP1, from cyclohexanone (**1**, 5.2 mL, 0.05 mol), ethyl cyanoacetate (5.7 mL, 0.05 mol), sulfur (1.6 g, 0.05 mol), morpholine (4.4 mL, 0.05 mol) and EtOH (15 mL) followed by re-crystallization of the crude product from EtOH, **4** (6.14 g, 54.5%) was obtained as an off-white solid; R_f = 0.43 (SiO₂, *n*-hexane/ethyl acetate, 9:1); m.p.: 115 – 117°C (lit.:⁶⁵ 115°C).

IR (ATR): ν = 3402 m , 3296 m , 2939 w , 1645 s , 1595 s , 1575 s , 1490 s , 1273 vs , 1152 s cm⁻¹;

UV/Vis (MeOH): λ_{max} (log ϵ) = 209 nm (4.01);

¹H NMR (400 MHz, CDCl₃): δ = 5.94 (*s*, 2H, -NH₂, H-2), 4.25 (*q*, *J* = 7.1 Hz, 2H, H-11), 2.77 – 2.65

(*m*, 2H, H-7), 2.54 – 2.44 (*m*, 2H, H-4), 1.81 – 1.71 (*m*, 3H, H-5 + H-6), 1.33 (*t*, *J* = 7.1 Hz, 3H, H-12) ppm; ¹³C NMR (101 MHz, CDCl₃): δ = 166.0 (C-10), 160.8 (C-2), 132.5 (C-9), 118.2 (C-8), 106.4 (C-3), 59.4 (C-11), 26.9 (C-7), 24.5 (C-4), 23.2 (C-5), 22.8 (C-6), 14.4 (C-12) ppm;

MS (ESI, MeOH/CHCl₃ = 4:1): *m/z* = 226.1 ([M+H]⁺, 77%), 248.1 ([M+Na]⁺, 15%).

2-Amino-4-methyl-4,5,6,7-tetrahydro-benzo[b]-thiophene-3-carboxylic acid ethyl ester (**5**)

Following GP1 from 2-methylcyclohexanone (**2**, 5.2 mL, 0.05 mol), ethyl cyanoacetate (5.7 mL, 0.05 mol), sulfur (1.6 g, 0.05 mol), morpholine (4.4 mL, 0.05 mol) and EtOH (15 mL) followed by chromatography (SiO₂, *n*-hexane/ethyl acetate, 95:5) **5** (9.96 g, 83.2%) was obtained as a yellowish solid; R_f = 0.25 (SiO₂, *n*-hexane/ethyl acetate, 95:5); m.p.: 74 – 76°C (lit.:⁶⁶ 73°C);

IR (ATR): ν = 3411 m , 3304 m , 2942 m , 1641 vs , 1591 vs , 1568 vs , 1486 s , 1277 vs , 1149 s cm⁻¹;

UV/Vis (MeOH): λ_{max} (log ϵ) = 230 nm (4.39);

¹H NMR (400 MHz, DMSO-*d*₆): δ = 7.20 (*s*, 2H, -NH₂, H-2), 4.25 – 4.05 (*m*, 2H, H-11), 3.19 – 3.09 (*m*, 1H, H-4), 2.47 – 2.30 (*m*, 2H, H-7), 1.84 – 1.47 (*m*, 4H, H-6 + H-5), 1.24 (*t*, *J* = 7.1 Hz, 3H, H-12), 1.07 (*d*, *J* = 6.7 Hz, 3H, H-13) ppm;

¹³C NMR (101 MHz, DMSO-*d*₆): δ = 165.2 (C-10), 163.8 (C-2), 137.0 (C-9), 115.6 (C-8), 102.5 (C-3), 59.1 (C-11), 29.9 (C-4), 29.4 (C-5), 24.4 (C-7), 21.95 (C-12), 18.4 (C-6), 14.7 (C-13) ppm;

MS (ESI, MeOH): *m/z* = 240.4 ([M+H]⁺, 52%), 262.4 ([M+Na]⁺, 100%).

2-Amino-5-methyl-4,5,6,7-tetrahydro-benzo[b]-thiophene-3-carboxylic acid ethyl ester (**6**)

Following GP1 from 3-methylcyclohexanone (**3**, 5.2 mL, 0.05 mol), ethyl cyanoacetate (5.7 mL, 0.05 mol), sulfur (1.6 g, 0.05 mol), morpholine (4.4 mL, 0.05 mol) and EtOH (15 mL) followed by chromatography (SiO₂, *n*-hexane/ethyl acetate, 95:5) **6** (10.12 g, 84.6%) was obtained as a yellowish solid; R_f = 0.25 (SiO₂, *n*-hexane/ethyl acetate, 95:5); m.p.: 71 – 73°C (lit.:⁶⁷ 70 – 71°C);

IR (ATR): $\nu = 3424m, 3312m, 2946m, 1644s, 1578s, 1487vs, 1274vs, 1163s \text{ cm}^{-1}$;
 UV/Vis (MeOH): $\lambda_{\text{max}} (\log \epsilon) = 229 \text{ nm} (4.39)$;
 $^1\text{H NMR}$ (400 MHz, CDCl_3): $\delta = 5.87 (s, 2H, -NH_2, H-2), 4.26 (q, J = 7.1, 0.9 \text{ Hz}, 2H, H-12), 2.97 - 2.86 (m, 2H, H-4), 2.58 - 2.48 (m, 2H, H-7), 2.18 (ddt, J = 17.2, 9.5, 2.4 \text{ Hz}, 1H, H-5), 1.93 - 1.70 (m, 1H, H-6a), 1.46 - 1.34 (m, 1H, H-6b), 1.33 (t, J = 7.1 \text{ Hz}, 3H, H-12), 1.04 (d, J = 6.6 \text{ Hz}, 3H, H-13) \text{ ppm}$;
 $^{13}\text{C NMR}$ (101 MHz, CDCl_3): $\delta = 165.9 (C-10), 161.0 (C-2), 132.5 (C-9), 117.8 (C-8), 106.2 (C-3), 59.4 (C-11), 35.3 (C-6), 31.3 (C-4), 28.9 (C-5), 24.3 (C-7), 21.7 (C-13), 14.5 (C-12) \text{ ppm}$;
 MS (ESI, MeOH): $m/z = 240.1 ([M+H]^+, 60\%), 262.1 ([M+Na]^+, 14\%)$.

5 α -Cholestan-3-one (8)

Following GP2 from (+)-dihydrocholesterol (**7**, 2.51 g, 6.47 mmol), acetone (125 mL), CrO_3 (0.78 g, 7.76 mmol), dist. H_2O (2.5 mL), conc. H_2SO_4 (0.75 mL) and silica gel (20 mL) followed by chromatography (SiO_2 , *n*-hexane/ethyl acetate, 95:5) **8** (2.19 g, 87.5%) was obtained as a colorless solid; $R_f = 0.32$ (SiO_2 , *n*-hexane/ethyl acetate, 95:5); m.p.: 127 – 129°C (lit.:⁶⁸ 128 – 129°C);
 IR (ATR): $\nu = 2931s, 2866s, 1713vs, 1444m, 1454m, 1376m, 1384m \text{ cm}^{-1}$;
 $[\alpha]_D^{20} = +40.83^\circ (c = 0.49, \text{CHCl}_3)$;
 $^1\text{H NMR}$ (500 MHz, CHCl_3): $\delta = 2.41 - 2.32 (m, 1H, H-2a), 2.32 - 2.21 (m, 2H, H-2b + H-4a), 2.06 (ddd, J = 15.0, 3.9, 2.3 \text{ Hz}, 1H, H-4b), 2.03 - 1.95 (m, 2H, H-1a + H-24a), 1.86 - 1.76 (m, 1H, H-16a), 1.72 - 1.65 (m, 1H, H-7a), 1.60 - 1.46 (m, 5H, H-15 + H-11a + H-25 + H-5), 1.42 - 1.29 (m, 8H, H-1b + H-6 + H-11b + H-20 + H-22a + H-23a + H-8), 1.29 - 1.19 (m, 1H, H-16b), 1.17 - 1.06 (m, 5H, H-12 + H-23b + H-24 + H-14), 1.07 - 0.92 (m, 2H, H-22b, H-17), 0.99 (s, 3H, H-19), 0.92 - 0.87 (m, 4H, H-7b + H-21), 0.85 (dd, $J = 6.6, 2.2 \text{ Hz}, 6H, H-26 + H-27), 0.80 - 0.68 (m, 1H, H-9), 0.67 (s, 3H, H-18) \text{ ppm}$;
 $^{13}\text{C NMR}$ (125 MHz, CDCl_3): $\delta = 212.0 (C-3), 56.3 (C-14), 56.3 (C-17), 53.8 (C-9), 46.7 (C-5), 44.7 (C-4), 42.6 (C-13), 39.9 (C-24), 39.5 (C-12), 38.6 (C-1), 38.2 (C-2), 36.1 (C-22), 35.8 (C-20), 35.6 (C-10), 35.4 (C-8), 31.7 (C-7), 29.0 (C-6), 28.2 (C-16), 28.0 (C-25), 24.2 (C-15), 23.8 (C-23), 22.8 (C-26), 22.5 (C-27), 21.4 (C-11), 18.7 (C-21), 12.1 (C-18), 11.4 (C-19) \text{ ppm}$;
 MS (ASAP): $m/z = 387.4 ([M+H]^+, 100\%)$.$

3 β , 5 α -Sitostanol (9)

Hydrogenation of stigmaterol (**10**, 5.0 g, 12.12 mmol) in THF:MeOH (2:1, 150 mL) with Pd/C (10%, 500 mg) for 48 h and 5 bar H_2 pressure followed by usual work-up and chromatography (SiO_2 , *n*-hexane/ethyl acetate, 85:15) gave **9** (4.17 g, 83.4%) as a colorless solid; $R_f = 0.29$ (SiO_2 , *n*-hexane/ethyl acetate, 85:15); m.p.: 129 – 131°C (lit.:⁶⁹ 134 – 136°C);
 IR (ATR): $\nu = 3271br, 2956s, 2932vs, 1466m, 1449m, 1375s, 1044s \text{ cm}^{-1}$;

$[\alpha]_D^{20} = +17.16^\circ (c = 0.40, \text{CHCl}_3)$; $^1\text{H NMR}$ (500 MHz, CHCl_3): $\delta = 3.59 (m, J = 10.7, 4.8 \text{ Hz}, 1H, H-3), 2.34 - 2.24 (m, 1H, OH), 1.95 (dt, J = 12.7, 3.5 \text{ Hz}, 1H, H-12a), 1.86 - 1.75 (m, 2H, H-6a + H-7a), 1.73 - 1.61 (m, 3H, H-1a + H-4a + H-25), 1.60 - 1.51 (m, 2H, H-2a + H-15a), 1.51 - 1.37 (m, 2H, H-7b + H-11a), 1.37 - 1.19 (m, 9H, H-2b + H-8 + H-11b + H-16 + H-20 + H-22a + H-28), 1.19 - 1.06 (m, 6H, H-5 + H-12 + H-14 + H-23), 1.06 - 0.94 (m, 3H, H-15b + H-17 + H-22b), 0.94 - 0.87 (m, 5H, H-1b + H-21 + H-24), 0.85 (s, 1H, H-4b), 0.84 - 0.80 (m, 9H, H-18 + H-26 + H-27), 0.80 (s, 3H, H-19), 0.70 - 0.57 (m, 4H, H-9 + H-29) ppm;
 $^{13}\text{C NMR}$ (125 MHz, CDCl_3): $\delta = 71.4 (C-3), 56.5 (C-17), 56.2 (C-14), 54.4 (C-9), 45.8 (C-24), 44.9 (C-5), 42.6 (C-13), 40.0 (C-12), 38.1 (C-2), 37.0 (C-1), 36.2 (C-20), 35.5 (C-8), 35.5 (C-10), 33.9 (C-22), 32.1 (C-4), 31.4 (C-7), 29.2 (C-25), 28.7 (C-16), 28.3 (C-6), 26.1 (C-23), 24.2 (C-15), 23.1 (C-28), 21.3 (C-11), 19.8 (C-27), 19.0 (C-26), 18.7 (C-21), 12.3 (C-19), 12.1 (C-29), 12.0 (C-18), ppm$;
 MS (ASAP): $m/z = 397.4 ([M-H_2O-H]^-, 80\%)$.$

5 α -Sitostan-3-one (11)

Following GP2, from **9** (2.70 g, 6.47 mmol), acetone (125 mL), CrO_3 (0.78 g, 7.76 mmol), dist. H_2O (2.5 mL), conc. H_2SO_4 (0.75 mL) and silica gel (20 mL) followed by chromatography (SiO_2 , *n*-hexane/ethyl acetate, 85:15 und 9:1) **11** (1.60 g, 59.7%) was obtained as a colorless solid; $R_f = 0.23$ (SiO_2 , *n*-hexane/ethyl acetate, 85:15); m.p.: 153 – 155°C (lit.:⁷⁰ 155°C);
 IR (ATR): $\nu = 2931s, 2959s, 1716vs, 1443m, 1435m \text{ cm}^{-1}$;
 $[\alpha]_D^{20} = +40.52^\circ (c = 0.42, \text{CHCl}_3)$;
 $^1\text{H NMR}$ (500 MHz, CHCl_3): $\delta = 2.41 - 2.32 (m, 1H, H-2a), 2.31 - 2.21 (m, 2H, H-2b + H-4a), 2.10 - 2.04 (m, 1H, H-4b), 2.03 - 1.95 (m, 2H, H-1a + H-12a), 1.87 - 1.78 (m, 1H, H-16a), 1.72 - 1.61 (m, 2H, H-7a + H-25), 1.60 - 1.47 (m, 3H, H-5 + H-11a + H-15a), 1.43 - 1.22 (m, 9H, H-1b + H-6 + H-8 + H-11b + H-16b + H-20 + H-22a + H-28a), 1.21 - 1.08 (m, 5H, H-12b + H-14 + H-23 + H-28b), 1.07 - 0.95 (m, 3H, H-15b + H-17 + H-22b), 0.99 (s, 3H, H-19), 0.95 - 0.86 (m, 5H, H-7b + H-21 + H-24), 0.86 - 0.79 (m, 9H, H-26 + H-27 + H-29), 0.79 - 0.68 (m, 1H, H-9), 0.67 (s, 3H, H-18) ppm;
 $^{13}\text{C NMR}$ (125 MHz, CDCl_3): $\delta = 212.0 (C-3), 56.3 (C-17), 56.2 (C-14), 53.8 (C-9), 46.7 (C-5), 45.8 (C-24), 44.7 (C-4), 42.6 (C-13), 39.9 (C-12), 38.6 (C-1), 38.2 (C-2), 36.1 (C-20), 35.6 (C-10), 35.4 (C-8), 33.9 (C-22), 31.7 (C-7), 29.2 (C-25), 29.0 (C-6), 28.2 (C-16), 26.1 (C-23), 24.2 (C-15), 23.1 (C-28), 21.4 (C-11), 19.8 (C-26), 19.0 (C-27), 18.7 (C-21), 12.0 (C-18), 12.0 (C-29), 11.4 (C-19) ppm$;
 MS (ASAP): $m/z = 415.4 ([M+H]^+, 100\%)$.$

5'-Amino-cholest-2-eno[2,3-b]thiophene-4'-carboxylic acid ethyl ester (12)

Following GP1 from **8** (402 mg, 1.04 mmol), ethyl cyanoacetate (0.12 mL, 1.04 mmol), sulfur (32 mg, 1.04 mmol), morpholine (0.1 mL, 1.04 mmol) and

EtOH (10 mL) followed by chromatography (SiO₂, *n*-hexane/ethyl acetate, 95:5) **12** (308 mg, 57.6%) was obtained as a colorless solid; R_f = 0.28 (SiO₂, *n*-hexane/ethyl acetate, 95:5); m.p.: 177 – 180°C (lit.:³⁸ 181°C);

IR (ATR): $\nu = 3485w, 3356w, 2927m, 1665vs, 1598m, 1497m, 1268w, 1160m$ cm⁻¹;

UV/Vis (MeOH): $\lambda_{max}(\log \epsilon) = 229$ nm (4.01);

$[\alpha]_D^{20} = +69.52^\circ$ ($c = 0.35$, CHCl₃); ¹H NMR (500 MHz, CHCl₃): $\delta = 5.90$ (*s*, 2H, -NH₂, H-5'),

4.34 – 4.19 (*m*, 2H, H-29), 2.79 – 2.70 (*m*, 1H, H-4a), 2.46 – 2.39 (*m*, 1H, H-1a), 2.23 – 2.13 (*m*, 2H, H-1b + H-4b), 2.00 (*dt*, $J = 12.6, 3.5$ Hz, 1H, H-12a),

1.87 – 1.76 (*m*, 1H, H-16a), 1.73 – 1.66 (*m*, 1H, H-6a), 1.63 – 1.46 (*m*, 3H, H-7a + H-15a + H-25),

1.49 – 1.20 (*m*, 8H, H-5 + H-7b + H-8 + H-11 + H-16b + H-20 + H-23a), 1.33 (*t*, $J = 7.1$ Hz, 3H,

H-30), 1.20 – 1.02 (*m*, 6H, H-12b H-15b + H-17 + H-23b + H-24), 1.05 – 0.92 (*m*, 3H, H-14 + H-22),

0.95 – 0.84 (*m*, 10H, H-6b + H-21 + H-26 + H-27), 0.83 – 0.73 (*m*, 1H, H-9), 0.78 (*s*, 3H, H-19), 0.67

(*s*, 3H, H-18) ppm; ¹³C NMR (125 MHz, CDCl₃): $\delta = 165.9$ (C-28), 160.1 (C-5'), 131.2 (C-3), 118.2

(C-2), 106.5 (C-4'), 59.5 (C-29), 56.4 (C-14), 56.3

(C-17), 53.8 (C-9), 42.5 (C-13), 41.7 (C-5), 39.9

(C-12), 39.5 (C-24), 38.7 (C-1), 36.2 (C-22), 36.2

(C-10), 35.8 (C-20), 35.7 (C-8), 31.9 (C-4), 31.8

(C-6), 28.9 (C-7), 28.2 (C-16), 28.0 (C-25), 24.2

(C-15), 23.9 C (C-23), 22.8 (C-27), 22.6 (C-26), 21.1

(C-11), 18.7 (C-21), 14.5 (C-30), 12.0 (C-18), 11.6

(C-19) ppm;

MS (ESI, MeOH/CHCl₃ = 4:1): $m/z = 514.3$ ([M+H]⁺, 100%);

analysis calcd for C₃₂H₅₂N₂O₂S (513.83): C 74.80, H 10.00, N 2.73, S 6.24; found: C 74.57, H 10.16, N 2.52, S 6.01.

5'-Amino-cholest-2-enof[2,3-b]thiophene-4'-carboxylic acid *n*-propyl ester (**13**)

Following GP1, from **8** (402 mg, 1.04 mmol), propyl cyanoacetate (0.13 mL, 1.04 mmol), sulfur (32 mg, 1.04 mmol), morpholine (0.1 mL, 1.04 mmol) and EtOH (15 mL) followed by chromatography (SiO₂, *n*-hexane/ethyl acetate, 95:5) gave **13** (367 mg, 0.70 mmol, 66.9%) as an off-white solid; R_f = 0.33 (SiO₂, *n*-hexane/ethyl acetate, 95:5); m.p.: 161 – 163°C;

IR (ATR): $\nu = 3484w, 3354w, 2928m, 1665vs, 1599m, 1587m, 1497s, 1268w, 1160m$ cm⁻¹;

UV/Vis (MeOH): $\lambda_{max}(\log \epsilon) = 230$ nm (4.01); $[\alpha]_D^{20} = +70.91^\circ$ ($c = 0.41$, CHCl₃);

¹H NMR (500 MHz, CHCl₃): $\delta = 5.90$ (*s*, 2H, -NH₂, H-5'), 4.33 – 4.11 (*m*, 2H, H-29), 2.80 – 2.71 (*m*, 1H, H-6a), 2.43 (*d*, $J = 15.4$ Hz, 1H, H-1a), 2.23 – 2.15

(*m*, 2H, H-1b + H-6b), 2.00 (*dt*, $J = 12.6, 3.4$ Hz, 2H, H-12), 1.87 – 1.77 (*m*, 1H, H-7a), 1.77 – 1.67 (*m*, 3H, H-4a + H-30), 1.63 – 1.56 (*m*, 2H, H-15), 1.56 – 1.49

(*m*, 2H, H-16a + H-25), 1.48 – 1.40 (*m*, 3H, H-5 + H-11), 1.39 – 1.29 (*m*, 5H, H-8 + H-16b + H-20 + H-22a + H-23a), 1.29 – 1.19 (*m*, 1H, H-7b), 1.19 – 1.03

(*m*, 4H, H-17 + H-23b + H-24), 1.03 – 0.95

(*m*, 5H, H-14 + H-22b + H-31), 0.95 – 0.84 (*m*, 10H, H-4b + H-21 + H-26 + H-27), 0.84 – 0.72 (*m*, 1H,

H-9), 0.78 (*s*, 3H, H-19), 0.67 (*s*, 3H, H-18) ppm;

¹³C NMR (125 MHz, CDCl₃): $\delta = 166.1$ (C-28), 159.7

(C-5'), 131.2 (C-3), 118.4 (C-2), 106.8 (C-4'), 65.3

(C-29), 56.4 (C-14), 56.3 (C-17), 53.8 (C-9), 42.5

(C-13), 41.7 (C-5), 39.9 (C-12), 39.5 (C-24), 38.7

(C-1), 36.2 (C-10), 36.2 (C-22), 35.8 (C-20), 35.7

(C-8), 31.9 (C-6), 31.7 (C-4), 29.0 (C-16), 28.2 (C-7),

28.0 (C-25), 24.2 (C-15), 23.9 (C-23), 22.8 (C-27),

22.6 (C-26), 22.2 (C-30), 21.1 (C-11), 18.7 (C-21),

12.0 (C-18), 11.6 (C-19), 10.8 (C-31) ppm;

MS (ESI, MeOH/CHCl₃ = 4:1): $m/z = 528.1$ ([M+H]⁺, 100%);

analysis calcd for C₃₃H₅₃N₂O₂S (527.38): C 75.09, H 10.12, N 2.65, S 6.07; found: C 74.86, H 12.40, N 2.46, S 5.83.

5'-Amino-sitost-2-enof[2,3-b]thiophene-4'-carboxylic acid ethyl ester (**14**)

Following GP1 from **11** (431 mg, 1.04 mmol), ethyl cyanoacetate (0.12 mL, 1.04 mmol), sulfur (32 mg, 1.04 mmol), morpholine (0.1 mL, 1.04 mmol) and EtOH (15 mL) followed by chromatography (SiO₂, *n*-hexane/ethyl acetate, 95:5) **14** (348 mg, 0.64 mmol, 61.8%) was obtained as an off-white solid; R_f = 0.27 (SiO₂, *n*-hexane/ethyl acetate, 95:5); m.p.: 196 – 198°C;

IR (ATR): $\nu = 3476w, 3346w, 2929s, 1663vs, 1595m, 1584m, 1494m, 1269m, 1161m$ cm⁻¹;

UV/Vis (MeOH): $\lambda_{max}(\log \epsilon) = 229$ nm (4.01); $[\alpha]_D^{20} = +68.69^\circ$ ($c = 0.33$, CHCl₃);

¹H NMR (500 MHz, CHCl₃): $\delta = 5.94$ (*s*, 2H, -NH₂, H-5'), 4.37 – 4.16 (*m*, 2H, H-31), 2.75 (*dd*, $J = 17.9,$

5.1 Hz, 1H, H-6a), 2.43 (*d*, $J = 15.2$ Hz, 1H, H-1a),

2.24 – 2.14 (*m*, 2H, H-1b + H-6b), 2.00 (*dt*, $J = 12.6,$

3.5 Hz, 1H, H-12a), 1.88 – 1.78 (*m*, 1H, H-16a), 1.73

– 1.62 (*m*, 2H, H-4a + H-25), 1.62 – 1.50 (*m*, 2H,

H-7a + H-15a), 1.48 – 1.37 (*m*, 3H, H-5 + H-11), 1.33

(*t*, $J = 7.1$ Hz, 6H, H-8 + H-20 + H-22a + H-32), 1.30

– 1.21 (*m*, 4H, H-7b + H-16b + H-28), 1.21 – 1.10

(*m*, 4H, H-12b + H-17 + H-23), 1.10 – 0.97 (*m*, 3H,

H-14 + H-15b + H-22b), 0.95 – 0.88 (*m*, 5H, H-4b + H-21 + H-24), 0.87 – 0.79 (*m*, 9H, H-26 + H-27 + H-29), 0.78 (*m*, 4H, H-9 + H-19), 0.67 (*s*, 3H, H-18)

ppm; ¹³C NMR (125 MHz, CDCl₃): $\delta = 165.9$ (C-30), 159.5 (C-5'), 131.3 (C-3), 118.6 (C-2), 106.9 (C-4'), 59.5 (C-31), 56.4 (C-14), 56.2 (C-17), 53.8 (C-9), 45.8 (C-24), 42.5 (C-13), 41.7 (C-5), 39.9 (C-12), 38.8 (C-1), 36.2 (C-10), 36.2 (C-20), 35.7 (C-8), 33.9

(C-22), 31.9 (C-6), 31.8 (C-4), 29.2 (C-25), 28.9

(C-7), 28.2 (C-16), 26.1 (C-23), 24.2 (C-15),

23.1 (C-28), 21.1 (C-11), 19.8 (C-26), 19.0 (C-27),

18.8 (C-21), 14.5 (C-32), 12.0 (C-18 + C-29),

11.6 (C-19), ppm; MS (ESI, MeOH/CHCl₃ = 4:1): $m/z = 542.1$ ([M+H]⁺, 100%);

analysis calcd for C₃₄H₅₅N₂O₂S (541.88): C 75.36, H 10.23, N 2.58, S 5.92; found: C 75.15, H 10.46, N 2.41, S 5.77.

5'-Amino-sitost-2-enof[2,3-b]thiophene-4'-carboxylic acid *n*-propyl ester (**15**)

Following GP1, from **11** (431 mg, 1.04 mmol), propyl cyanoacetate (0.13 mL, 1.04 mmol), sulfur (32 mg,

1.04 mmol), morpholine (0.1 mL, 1.04 mmol) and EtOH (15 mL) followed by chromatography (SiO₂, *n*-hexane/ethyl acetate, 95:5) **15** (372 mg, 64.3%) was obtained as a colorless solid; *R*_f = 0.29 (SiO₂, *n*-hexane/ethyl acetate, 95:5); m.p.: 174 – 176°C; IR (ATR): $\nu = 3442w, 3325w, 2927s, 1663vs, 1593s, 1582s, 1481s, 1268vs, 1159s \text{ cm}^{-1}$; UV/Vis (MeOH): $\lambda_{\text{max}} (\log \epsilon) = 230 \text{ nm} (4.01)$; $[\alpha]_D^{20} = +67.20^\circ (c = 0.32, \text{CHCl}_3)$; ¹H NMR (500 MHz, CHCl₃): $\delta = 5.93 (s, 2H, -NH_2, H-5')$, $4.17 (qt, J = 10.7, 6.6 \text{ Hz}, 2H, H-31)$, $2.80 - 2.73 (m, 1H, H-6a)$, $2.43 (d, J = 15.4 \text{ Hz}, 1H, H-1a)$, $2.24 - 2.14 (m, 2H, H-1b + H-6b)$, $2.00 (dt, J = 12.6, 3.4 \text{ Hz}, 1H, H-12a)$, $1.88 - 1.78 (m, 1H, H-7a)$, $1.78 - 1.63 (m, 4H, H-4a + H-25 + H-32)$, $1.63 - 1.49 (m, 2H, H-15a + H-16a)$, $1.48 - 1.37 (m, 3H, 5 + H-11)$, $1.37 - 1.29 (m, 4H, H-8 + H-16b + H-20 + H-22a)$, $1.29 - 1.21 (m, 3H, H-7b + H-28)$, $1.21 - 1.08 (m, 4H, H-12b + H-17 + H-23)$, $1.07 - 0.97 (m, 6H, H-14 + H-15b + H-22b + H-33)$, $0.95 - 0.88 (m, 5H, H-4b + H-21 + H-24)$, $0.87 - 0.79 (m, 9H, H-26 + H-27 + H-29)$, $0.79 - 0.74 (m, 4H, H-9 + H-19)$, $0.67 (s, 3H, H-18) \text{ ppm}$; ¹³C NMR (125 MHz, CDCl₃): $\delta = 166.1 (C-30)$, $159.8 (C-5')$, $131.2 (C-3)$, $118.4 (C-2)$, $106.8 (C-4')$, $65.3 (C-31)$, $56.4 (C-14)$, $56.2 (C-17)$, $53.8 (C-9)$, $45.8 (C-24)$, $42.5 (C-13)$, $41.7 (C-5)$, $39.9 (C-12)$, $38.7 (C-1)$, $36.2 (C-10)$, $36.2 (C-20)$, $35.7 (C-8)$, $33.9 (C-22)$, $32.0 (C-6)$, $31.7 (C-4)$, $29.2 (C-25)$, $28.9 (C-16)$, $28.2 (C-7)$, $26.1 (C-23)$, $24.2 (C-15)$, $23.1 (C-28)$, $22.2 (C-32)$, $21.1 (C-11)$, $19.8 (C-26)$, $19.0 (C-27)$, $18.8 (C-21)$, $12.0 (C-18 + C-29)$, $11.6 (C-19)$, $10.8 (C-33) \text{ ppm}$; MS (ESI, MeOH/CHCl₃ = 4:1, ASAP): *m/z* = 556.1 ([M+H]⁺, 100%); C₃₅H₅₇NO₂S (555.91): C 75.62, H 10.34, N 2.52, S 5.77; found: C 75.34, H 10.46, N 2.37, S 5.51.

Acknowledgements

We would like to thank Th. Schmidt for measuring the MS spectra, Dr. D. Ströhl, Y. Schiller, and S. Ludwig for the NMR spectra. Many thanks are also due to M. Schneider for measuring the IR, UV/vis spectra, and microanalyses.

References

- 1- K.M. Elattar, A. El-Mekabaty, Heterocyclic steroids: Efficient routes and biological characteristics of steroidal fuse bicyclic pyrimidines, *J. Heterocycl. Chem.*, **2021**, 58, 389-414.
- 2- M.A. Gouda, M.A. Berghot, G.E. El-Ghani, K.M. Elattar, A.E.G.M. Khalil, Chemistry of 2-aminothiophene-3-carboxamide and related compounds, *Turk. J. Chem.*, **2011**, 35, 815-837.
- 3- M. Monier, A. El-Mekabaty, K.M. Elattar, Five-membered ring systems with one heteroatom: synthetic routes, chemical reactivity, and biological properties of furan-carboxamide analogs, *Synth. Commun.*, **2018**, 48, 839-875.
- 4- M. Monier, A. El-Mekabaty, D. Abdel-Latif, B.D. Mert, K.M. Elattar, Heterocyclic steroids: efficient routes for the annulation of pentacyclic steroidal pyrimidines, *Steroids*, **2020**, 154, 108548.
- 5- A. Bhalla, P. Saini, S.S. Bari, 2-aminothiophenes: a review on synthetic routes and applications (biological/synthons), *Am. J. PharmTech Res.*, **2017**, 7, 57-78.
- 6- K. Bozorov, L.F. Nie, J. Zhao, H.A. Aisa, 2-Aminothiophene scaffolds: Diverse biological and pharmacological attributes in medicinal chemistry, *Eur. J. Med. Chem.*, **2017**, 140, 465-493.
- 7- K. Gewald, Methods for the synthesis and reaction of 2-aminothiophenes, *Khim. Geterotsikl. Soedin.*, **1976**, 1299.
- 8- K. Gewald, Methods for the synthesis and reaction of 2-aminothiophenes, *Pyatichlen. Aromat. Geterotsikly*, Riga, **1979**, 85-101.
- 9- V.P. Litvinov, Y.A. Sharanin, F.S. Babichev, Cyclization of nitriles as synthetic route to 2- and 3-aminothiophenes, *Sulfur Rep.*, **1986**, 6, 97-135.
- 10- C. Paulmier, Synthesis and reactivity of 3-aminothiophenes and 3,4-diaminothiophenes, *Sulfur Rep.*, **1996**, 19, 215-284.
- 11- M. Perrissin, Substituted 2-aminothiophenes. Synthesis, structure, and reactivity. Pharmacological results, *Bull. Trav. Soc. Pharm. Lyon*, **1982**, 26, 76-79.
- 12- R. Aivelu, B. Mohanta, Y. Jahnavi, B.U. Kiran, S.K.K. Naresh, Design, synthesis of novel ethylene bridged N-Acyl homoserine lactones as inhibitors of quorum sensing signaling in pathogenic bacteria to prevent biofilm formation, *Int. J. Pharm. Biol. Sci.*, **2021**, 11, 56-65.
- 13- V. Duvauchelle, P. Meffre, Z. Benfodda, Recent contribution of medicinally active 2-aminothiophenes: A privileged scaffold for drug discovery, *Eur. J. Med. Chem.*, **2022**, 238, 114502.
- 14- Y. Hu, S. Yang, F.B. Shilliday, B.R. Heyde, K.M. Mandrell, R.H. Robins, J. Xie, M.T. Reding, Y. Lai, D.C. Thompson, Novel metabolic bioactivation mechanism for a series of anti-inflammatory agents (2,5-diaminothiophene derivatives) mediated by cytochrome P450 enzymes, *Drug Metab. Dispos.*, **2010**, 38, 1522-1531.
- 15- Y. Huang, A. Doemling, The Gewald multi-component reaction, *Mol. Diversity*, **2011**, 15, 3-33.
- 16- J. Hwang, X. Qiu, L. Borgelt, N. Haacke, L. Kanis, S. Petroulia, R. Gasper, D. Schiller, P. Lampe, S. Sievers, J. Imig, P. Wu, Synthesis and evaluation of RNase L-binding 2-aminothiophenes as anticancer agents, *Bioorg. Med. Chem.*, **2022**, 58, 116653.
- 17- M.E. Khalifa, W.M. Algotami, Gewald synthesis, antitumor profile and molecular modeling of novel 5-acetyl-4-((4-

- acetylphenyl)amino)-2-aminothiophene-3-carbonitrile scaffolds, *J. Mol. Struct.*, **2020**, 1207.
- 18-R.W. Sabnis, The Gewald reaction in dye chemistry, *Color. Technol.*, **2016**, 132, 49-82.
- 19-K. Gewald, Heterocycles from CH-acidic nitriles. VI. Reaction of methylene-active nitriles with mustard oils and sulfur, *J. Prakt. Chem. (Leipzig)*, **1966**, 32, 26-30.
- 20-K. Gewald, Heterocycles from CH-acidic nitriles. IX. Reaction of α -hydroxy ketones with malononitrile, *Chem. Ber.*, **1966**, 99, 1002-1007.
- 21-K. Gewald, Heterocycles from CH-acidic nitriles. V. Simultaneous action of sulfur and carbon disulfide on methylene-active nitriles, *J. Prakt. Chem. (Leipzig)*, **1966**, 31, 214-220.
- 22-K. Gewald, G. Neumann, H. Boettcher, Heterocycles from CH-acidic nitriles. XI. New synthesis of 2-aminothionaphthene, *Z. Chem.*, **1966**, 6, 261.
- 23-K. Gewald, E. Schinke, Heterocycles from CH-acidic nitriles. X. Reaction of acetone with cyanoacetic ester and sulfur, *Chem. Ber.*, **1966**, 99, 271-275.
- 24-K. Gewald, E. Schinke, H. Boettcher, Heterocycles from CH-acidic nitriles. VIII. 2-Aminothiophenes from methylene-active nitriles, carbonyl compounds, and sulfur, *Chem. Ber.*, **1966**, 99, 94-100.
- 25-B. Ganem, Strategies for Innovation in Multicomponent Reaction Design, *Acc. Chem. Res.*, **2009**, 42, 463-472.
- 26-B. Jiang, T. Rajale, W. Wever, S.-J. Tu, G. Li, Multi-component reactions for the synthesis of heterocycles, *Chem. Asian J.*, **2010**, 5, 2318-2335.
- 27-C.G. Neochoritis, T. Zhao, A. Doemling, Tetrazoles via Multi-component Reactions, *Chem. Rev.*, **2019**, 119, 1970-2042.
- 28-S. Protti, S. Garbarino, D. Ravelli, A. Basso, Photoinduced Multi-component Reactions, *Angew. Chem., Int. Ed.*, **2016**, 55, 15476-15484.
- 29-B.H. Rotstein, S. Zaretsky, V. Rai, A.K. Yudin, Small Heterocycles in Multi-component Reactions, *Chem. Rev.*, **2014**, 114, 8323-8359.
- 30-E. Ruijter, R. Scheffelaar, R.V.A. Orru, Multicomponent Reaction Design in the Quest for Molecular Complexity and Diversity, *Angew. Chem., Int. Ed.*, **2011**, 50, 6234-6246.
- 31-P. Slobbe, E. Ruijter, R.V.A. Orru, Recent applications of multi-component reactions in medicinal chemistry, *MedChemComm*, **2012**, 3, 1189-1218.
- 32-B.B. Toure, D.G. Hall, Natural Product Synthesis Using Multicomponent Reaction Strategies, *Chem. Rev.*, **2009**, 109, 4439-4486.
- 33-J.S.B. Forero, J. Jones, Jr., F.M. da Silva, The synthetic potential and chemical aspects of the Gewald reaction: application in the preparation of 2-aminothiophenes and related heterocycles, *Curr. Org. Synth.*, **2013**, 10, 347-365.
- 34-Z. Puterova, A. Krutosikova, D. Veghc, Gewald reaction: Synthesis, properties and applications of substituted 2-aminothiophenes, *ARKIVOC*, **2011**, 209-246.
- 35-R.W. Sabnis, The Gewald synthesis, *Sulfur Rep.*, **1994**, 16, 1-17.
- 36-R.W. Sabnis, D.W. Rangnekar, N.D. Sonawane, 2-Aminothiophenes by the Gewald reaction, *J. Heterocycl. Chem.*, **1999**, 36, 333-345.
- 37-Y.A. Sharanin, V.K. Promonenkov, 2'-Aminoandrost-2-eno[2,3-b]thiophenes, *Khim. Geterotsikl. Soedin.*, **1980**, 1564-1565.
- 38-N.R. Mohamed, G.A. Elmegeed, M. Younis, Studies on organophosphorus compounds VII: Transformation of steroidal ketones with Lawesson's reagent into thioxo and heterofused steroids. Results of antimicrobial and antifungal activity, *Phosphorus, Sulfur Silicon Relat. Elem.*, **2003**, 178, 2003-2017.
- 39-S. John, A.V. Sorokin, P.D. Thompson, Phytosterols and vascular disease, *Curr. Opin. Lipidol.*, **2007**, 18, 35-40.
- 40-F. Marangoni, A. Poli, Phytosterols and cardiovascular health, *Pharmacol. Res.*, **2010**, 61, 193-199.
- 41-M.D. Patel, P.D. Thompson, Phytosterols and vascular disease, *Atherosclerosis (Amsterdam, Neth.)*, **2006**, 186, 12-19.
- 42-G. Vilahur, S. Ben-Aicha, E. Diaz-Riera, L. Badimon, T. Padro, Phytosterols and Inflammation, *Curr. Med. Chem.*, **2019**, 26, 6724-6734.
- 43-F. Blanco-Vaca, L. Cedó, J. Julve, Phytosterols in Cancer: From Molecular Mechanisms to Preventive and Therapeutic Potentials, *Curr. Med. Chem.*, **2019**, 26, 6735-6749.
- 44-P.G. Bradford, A.B. Awad, Phytosterols as anticancer compounds, *Mol. Nutr. Food Res.*, **2007**, 51, 161-170.
- 45-V.R. Ramprasath, A.B. Awad, Role of phytosterols in cancer prevention and treatment, *J. AOAC Int.*, **2015**, 98, 735-738.
- 46-N. Shahzad, W. Khan, S. Md, A. Ali, S.S. Saluja, S. Sharma, F.A. Al-Allaf, Z. Abduljaleel, I.A.A. Ibrahim, A.F. Abdel-Wahab, M.A. Afify, S.S. Al-Ghamdi, Phytosterols as a natural anticancer agent: Current status and future perspective, *Biomed. Pharmacother.*, **2017**, 88, 786-794.
- 47-H. Tapiero, D.M. Townsend, K.D. Tew, Phytosterols in the prevention of human pathologies, *Biomed. Pharmacother.*, **2003**, 57, 321-325.
- 48-T.A. Woyengo, V.R. Ramprasath, P.J.H. Jones, Anticancer effects of phytosterols, *Eur. J. Clin. Nutr.*, **2009**, 63, 813-820.
- 49-N.P. Peet, S. Sunder, R.J. Barbuch, A.P. Vinogradoff, Mechanistic observations in the Gewald syntheses of 2-aminothiophenes, *J. Heterocycl. Chem.*, **1986**, 23, 129-134.
- 50-D.D. Xuan, Recent Achievement in the Synthesis of Thiophenes, *Mini-Rev. Org. Chem.*, **2021**, 18, 110-134.
- 51-M. Carmack, M. Behforouz, G.A. Berchtold, S.M. Berkowitz, D. Wiesler, R. Barone, The

- Willgerodt-Kindler reactions. 6. Isomerization of the carbonyl group in alkanones and cycloalkanones, *J. Heterocycl. Chem.*, **1989**, 26, 1305.
- 52-J.H. Cho, C. Djerassi, Sterols in marine invertebrates. Part 57. Stereostructure, synthesis and acid-catalyzed isomerization of hebestrol, a biosynthetically significant cyclopropyl-containing marine sterol, *J. Chem. Soc., Perkin Trans.*, **1987**, 1, 1307-1318.
- 53-B.F. Cravatt, A.H. Lichtman, Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system, *Curr. Opin. Chem. Biol.*, **2003**, 7, 469-475.
- 54-S. Gaetani, V. Cuomo, D. Piomelli, Anandamide hydrolysis: a new target for anti-anxiety drugs ?, *Trends Mol. Med.*, **2003**, 9, 474-478.
- 55-S. Kathuria, S. Gaetani, D. Fegley, F. Valino, A. Duranti, A. Tontini, M. Mor, G. Tarzia, G. La Rana, A. Calignano, A. Giustino, M. Tattoli, M. Palmery, V. Cuomo, D. Piomelli, Modulation of anxiety through blockade of anandamide hydrolysis, *Nature Med.*, **2003**, 9, 76-81.
- 56-S.G. Kinsey, S.T. O'Neal, J.Z. Long, B.F. Cravatt, A.H. Lichtman, Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay, *Pharmacol., Biochem. Behav.*, **2011**, 98, 21-27.
- 57-M. Maccarrone, A. Finazzi-Agro, Anandamide hydrolase: a guardian angel of human reproduction ?, *Trends Pharmacol. Sci.*, **2004**, 25, 353-357.
- 58-J. Cai, F.E. Cooke, B.S. Sherborne, Antagonists of the orexin receptors, *Expert Opin. Ther. Pat.*, **2006**, 16, 631-646.
- 59-J. Gatfield, C. Brisbare-Roch, F. Jenck, C. Boss, Orexin Receptor Antagonists: A New Concept In CNS Disorders? *ChemMedChem*, **2010**, 5, 1197-1214.
- 60-A.L. Gotter, A.J. Roecker, R. Hargreaves, P.J. Coleman, C.J. Winrow, J.J. Renger, Orexin receptors as therapeutic drug targets, *Prog. Brain Res.*, **2012**, 198, 163-188.
- 61-T.P. Lebold, P. Bonaventure, B.T. Shireman, Selective orexin receptor antagonists, *Bioorg. Med. Chem. Lett.*, **2013**, 23, 4761-4769.
- 62-L. Lin, J. Faraco, R. Li, H. Kadotani, W. Rogers, X. Lin, X. Qiu, P.J. De Jong, S. Nishino, E. Mignot, The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene, *Cell (Cambridge, Mass.)*, **1999**, 98, 365-376.
- 63-T.E. Scammell, C.J. Winrow, Orexin receptors: pharmacology and therapeutic opportunities, *Annu. Rev. Pharmacol. Toxicol.*, **2011**, 51, 243-266.
- 64-C.J. Winrow, J.J. Renger, Discovery and development of orexin receptor antagonists as therapeutics for insomnia, *Br. J. Pharmacol.*, **2014**, 171, 283-293.
- 65-M. Sridhar, R.M. Rao, N.H.K. Baba, R.M. Kumbhare, Microwave-accelerated Gewald reaction. Synthesis of 2-aminothiophenes, *Tetrahedron Lett.*, **2007**, 48, 3171-3172.
- 66-M. Perrissin, M. Favre, C. Luu-Duc, F. Bakri-Logeais, F. Huguet, G. Narcisse, Thieno[2.3-d]-4-pyrimidones: synthesis, structure and pharmacological properties, *Eur. J. Med. Chem.--Chim. Ther.*, **1984**, 19, 420-424.
- 67-Y.W. Dong, X. Jiang, T. Liu, Y. Ling, Q. Yang, L. Zhang, X.K. He, Structure-Based Virtual Screening, Compound Synthesis, and Bioassay for the Design of Chitinase Inhibitors, *J. Agr. Food Chem.*, **2018**, 66, 3351-3357.
- 68-H. Mora-Rado, L. Bialy, W. Czechtizky, M. Mendez, J.P.A. Harrity, An Alkyne Diboration/ 6π -Electrocyclization Strategy for the Synthesis of Pyridine Boronic Acid Derivatives, *Angew. Chem., Int. Ed.*, **2016**, 55, 5834-5836.
- 69-Y. Arai, N. Koide, F. Ohki, H. Ageta, L.L. Yang, K.Y. Yen, Fern constituents: triterpenoids isolated from leaflets of *Cyathea spinulosa*, *Chem. Pharm. Bull.*, **1994**, 42, 228-232.
- 70-R.A. Abramovitch, R.G. Micetich, Extractives from *Populus tremuloides* heartwood--structure and synthesis of tremulone, *Can. J. Chem.*, **1962**, 40, 2017-2022.